FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Growth Hormone

CJC-1295 no DAC 5mg

5mg GHRH research peptide

From€39.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-CJC-5MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why CJC-1295 no DAC Fascinates Researchers

CJC-1295 without DAC — more precisely designated Modified GRF(1-29) or Mod GRF 1-29 — is a synthetically optimised derivative of the first twenty-nine amino acids of growth hormone-releasing hormone, incorporating four strategic amino acid substitutions that enhance metabolic stability while preserving full GHRH receptor (GHRHR) agonism. It represents the gold standard GHRH peptide tool for basic research into pulsatile GH secretion dynamics.

From GHRH to Mod GRF(1-29): Structural Optimisation

Native GHRH(1-29) contains the full biological activity of the complete 44-residue hormone within its first 29 amino acids — a finding that enabled the development of a series of truncated and modified analogues. The modifications in CJC-1295 no DAC address the key vulnerabilities of the native peptide: substitution at position 2 (Ala→D-Ala) prevents DPP-4 cleavage; substitution at position 8 (Asn→Gln) eliminates asparagine deamidation; position 15 (Gly→Ala) improves conformational stability; and position 27 (Met→Leu) removes the oxidation-sensitive methionine residue. The result is a GHRH fragment with a substantially improved pharmacokinetic profile relative to native GHRH(1-29) while maintaining complete receptor selectivity.

Distinction from CJC-1295 with DAC

The "no DAC" designation is critical for understanding the compound's pharmacological character. CJC-1295 with DAC (Drug Affinity Complex) contains an additional lysine conjugated with a maleimide-derivatised fatty acid chain, enabling covalent binding to circulating albumin and dramatically extending plasma half-life to approximately 6–8 days. CJC-1295 no DAC lacks this modification, resulting in a plasma half-life comparable to other GHRH peptides (approximately 30 minutes), which produces a physiologically pulsatile GH secretory pattern rather than the sustained elevated GH levels produced by the DAC-containing version. For research applications requiring preserved pulse architecture of the GH axis, CJC-1295 no DAC is the pharmacologically appropriate choice.

Applications in GH Axis Research

CJC-1295 no DAC is used in research settings to acutely stimulate pituitary GH release, enabling study of somatotroph function, GH secretion kinetics, and downstream IGF-1 production in a manner that respects the endogenous pulsatile architecture of the GH axis. Combined with a growth hormone secretagogue (GHSR agonist such as ipamorelin), it can be used to study synergistic stimulation of the two converging inputs to pituitary GH secretion.

This content is for informational purposes only and reflects the state of preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for CJC-1295 no DAC 5mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting CJC-1295 no DAC investigation.

[01]
Ionescu M, Frohman LA. (2006) — Journal of Clinical Endocrinology & Metabolism

“Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog”

Detailed pharmacodynamic characterisation of GHRH analogue effects on GH pulse architecture. The study demonstrates that GHRH analogue stimulation amplifies GH pulse amplitude while preserving the pulsatile pattern dependent on endogenous somatostatin oscillations — a finding with important implications for research into physiological versus pharmacological GH axis stimulation.

View on PubMed
[02]
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. (2009) — Rejuvenation Research

“Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects”

Proteomic analysis of serum changes following GHRH analogue administration in healthy adult subjects. Beyond expected IGF-1 increases, the study identifies a broad set of plasma proteins altered by GH axis activation, providing a systems-level view of the downstream molecular consequences of GHRH receptor stimulation in humans.

View on PubMed
[03]
Alba M, Salvatori R. (2004) — Endocrinology

“A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated GH deficiency”

Genetic characterisation study establishing a GHRH knockout mouse model — a critical tool for understanding the GHRH-GH-IGF-1 axis. The model demonstrates that GHRH is essential for normal somatotroph development and GH secretory capacity, providing a genetic validation for GHRH receptor pharmacology as a strategy for modulating GH axis activity.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about CJC-1295 no DAC.

Same Category

Similar Compounds

Other Growth Hormone research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.